Prevalence of infectious diseases in patients with autoimmune blistering diseases.
Mycobacterium tuberculosis
autoimmune blistering disease
hepatitis B virus
immunosuppressive treatment
screening
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
20
08
2019
accepted:
05
01
2020
pubmed:
12
2
2020
medline:
7
1
2021
entrez:
12
2
2020
Statut:
ppublish
Résumé
A long-term immunosuppressive treatment can provoke latent infections. Autoimmune blistering diseases (AIBD) are mostly treated with systemic immunosuppressive agents. To prevent the reactivation or exacerbation of existing latent infections, patients must be screened for infectious diseases before immunosuppressive treatments are initiated. However, the prevalence of infectious diseases in AIBD remains to be elucidated. To evaluate the necessity of screening infectious diseases in AIBD, we retrospectively reviewed the clinical records of 215 patients at a single center with AIBD for hepatitis B virus (HBV), hepatitis C virus (HCV), Mycobacterium tuberculosis, Treponema pallidum, human T-cell leukemia virus type 1 (HTLV-1) and HIV infections. Approximately 40% of patients were infected with HBV. During systemic corticosteroid treatment, HBV DNA became positive in 3.4% of cases. Antibodies to HCV, interferon-γ release assays for M. tuberculosis and the T. pallidum latex agglutination test were positive in 0.6%, 6.6% and 1.2% cases, respectively. Neither HTLV-1 nor HIV infections were detected. In conclusion, checks for HBV and M. tuberculosis infections should be made before immunosuppressive treatments are started, because of the high prevalence of these potentially life-threatening infections. Other infections should be tested for depending on the patient's risk factors.
Identifiants
pubmed: 32043652
doi: 10.1111/1346-8138.15244
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
378-384Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Amagai M, Tanikawa A, Shimizu T et al. Japanese guidelines for the management of pemphigus. J Dermatol 2014; 41: 471-486.
Feliciani C, Joly P, Jonkman MF et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 2015; 172: 867-877.
Ikeda M, Yamamoto H, Kaneko M et al. Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan. Int J Clin Oncol 2016; 21: 1162-1166.
Watanabe R, Ishii T, Kobayashi H et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med 2014; 233: 129-133.
Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010; 31: 240-246.
Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011; 7: 141-147.
Visram A, Chan KKW, McGee P et al. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS ONE 2015; 10: e0120749.
Fukuda W, Hanyu T, Katayama M et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 2017; 76: 1051-1056.
Cholongitas E, Haidich A, Apostolidou-kiouti F, Chalevas P. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Annu Gastroenterol 2018; 31: 480-490.
Yang C-H, Wu T-S, Chiu C-T. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007; 157: 587-590.
Wong GL-H, Yuen BW-Y, Chan HL-Y et al. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int 2019; 39: 271-279.
Keith PJ, Wetter DA, Wilson JW, Lehman JS. Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. Br J Dermatol 2014; 171: 1307-1317.
Chan YC, Yosipovitch G. Suggested guidelines for screening and management of tuberculosis in patients taking oral glucocorticoids - an important but often neglected issue. J Am Acad Dermatol 2003; 49: 91-95.
Motaparthi K, Stanisic V, Van Voorhees AS et al. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol 2014; 70: 178-186.
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res 2018; 66: 255-270.
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res 2014; 44 (Suppl S1): 1-58.
Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 2015; 62: S76-S86.
Schweitzer A, Horn J, Mikolajczyk RT et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-1555.
Tanaka J, Koyama T, Mizui M et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011; 54: 185-195.
Tanaka J, Kumagai J, Katayama K et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol 2015; 21: 10274-10289.
Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
Urata Y, Uesato R, Tanaka D et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23.
Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and / or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-627.
Choi J, Lim Y-S. Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy. J Infect Dis 2017; 216: S778-S784.
Fang J, Li W, Peng X et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis. Int Urol Nephrol 2017; 49: 475-482.
Inoue J, Kondo Y, Wakui Y et al. Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy. Clin J Gastroenterol 2016; 9: 93-98.
Lin Y-C, Lee S-W, Yeh H-Z et al. The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy. Int J Clin Pharm 2018; 40: 163-168.
Kawatani T, Suou T, Tajima F et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67: 45-50.
Sheen IS, Liaw YF, Lin DY, Chu CM. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol 1996; 24: 525-531.
Lee HL, Bae SH, Jang B et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liv 2017; 11: 870-877.
Romero Gutierrez M, del Campo Terron S, Moreno Zamora A et al. Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C? J Med Virol 2014; 86: 758-764.
Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol 2018; 6: 296-305.
Tuberculosis Surveillance Center [homepage on the Internet]. Tuberculosis in Japan Annual report 2018. [Cited 10 Jul 2019.] Available from URL: http://www.jata.or.jp/english/dl/pdf/TB_in_Japan_2018.pdf.
Hasan T, Au E, Chen S et al. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 2018; 8: e022445.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
Mori T, Harada N, Higuchi K et al. Waning of the specific interferon-gamma response after years of tuberculosis infection. Int J Tuberc Lung Dis 2007; 11: 1021-1025.
Millar JW, Horne NW. Tuberculosis in immunosuppressed patients. Lancet 1979; 1: 1176-1178.
Sahn SA, Lakshminarayan S. Tuberculosis after corticosteroid therapy. Br J Dis Chest 1976; 70: 195-205.
Getahun H, Matteelli A, Abubakar I et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.
National Institute of Infectious Disease. Syphilis 2008-2014. Infect Agents Surveill Rep 2015; 36: 17-19.
National Institute of Infectious Disease. HIV/AIDS in Japan, 2017. Infect Agents Surveill Rep 2018; 39: 149-150.
Minakami H, Maeda T, Fujii T et al. Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition. J Obstet Gynaecol Res 2014; 40: 1469-1499.
Satake M, Iwanaga PM, Sagara Y et al. Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide. Lancet Infect Dis 2016; 16: 1246-1254.